Cargando…

Allel RET+3 : T a medullary thyroid cancer

Detalles Bibliográficos
Autores principales:	Pławski, A, Podralska, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108166/ http://dx.doi.org/10.1186/1897-4287-9-S2-A12

Ejemplares similares

RET gene mutations spectrum in patients with medullary thyroid carcinoma (MTC) from Great Poland region
por: Kaczmarek-Ryś, Marta, et al.
Publicado: (2015)

Participation of miRNA in conditioning the incidence and modification of the course of FAP
por: Pławski, A, et al.
Publicado: (2011)

DNA bank for Polish patients with predispositions to occurrence of colorectal polyposis
por: Pławski, A, et al.
Publicado: (2011)

Absence of the RET+3:T allele in the MTC patients
por: Borun, Pawel, et al.
Publicado: (2012)

Medullary carcinoma of the thyroid: an update
por: Alevizaki, Maria
Publicado: (2013)

Novel Point Mutations and Allele Loss at the RET Locus in Sporadic Medullary Thyroid Carcinomas
por: Uchino, Shinya, et al.
Publicado: (1998)

RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency
por: Ramone, Teresa, et al.
Publicado: (2020)

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
por: Romei, Cristina, et al.
Publicado: (2018)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

RET mutations in a large indian family with medullary thyroid carcinoma
por: Mahesh, D. M., et al.
Publicado: (2014)

Effect of 3′UTR RET Variants on RET mRNA Secondary Structure and Disease Presentation in Medullary Thyroid Carcinoma
por: Ceolin, Lucieli, et al.
Publicado: (2016)

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency
por: Milićević, Sara, et al.
Publicado: (2021)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
por: Sahakian, Nicolas, et al.
Publicado: (2023)

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection
por: Huang, Qin, et al.
Publicado: (2020)

Modifier Role of Common RET Variants in Sporadic Medullary Thyroid Carcinoma
por: Skalniak, Anna, et al.
Publicado: (2021)

Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
por: Moura, M M, et al.
Publicado: (2009)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Somatic Mutations in the RET Protooncogene in Japanese and Chinese Sporadic Medullary Thyroid Carcinomas
por: Shan, Liang, et al.
Publicado: (1998)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma
por: Bim, Larissa V., et al.
Publicado: (2019)

Corrigendum: Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations
por: Oczko-Wojciechowska, Malgorzata, et al.
Publicado: (2017)

Cyclin D1 and CHEK2 polymorphic variants as low risk susceptibility alleles in DTC patients
por: Hryhorowicz, Szymon, et al.
Publicado: (2015)

RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation
por: Yue, Chia-Herng, et al.
Publicado: (2021)

Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey
por: Aydoğan, Berna İmge, et al.
Publicado: (2016)

A Korean Family of Familial Medullary Thyroid Cancer with Cys618Ser RET Germline Mutation
por: Jung, Jinhyang, et al.
Publicado: (2010)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

Diagnostic performance evaluation of post-operative serum calcitonin (CT) levels as a factor for good prognosis in medullary thyroid carcinoma (MTC)
por: Gąsior-Perczak, Danuta, et al.
Publicado: (2013)

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes
por: Alqahtani, Tariq, et al.
Publicado: (2023)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2015)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

Large‐scale Analysis of Mutations in RET Exon 16 in Sporadic Medullary Thyroid Carcinomas in Japan
por: Takano, Torn, et al.
Publicado: (2001)

Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity
por: Alqahtani, Tariq, et al.
Publicado: (2021)

SAT540 A Case of Simultaneous Medullary Thyroid Cancer (MTC) And Papillary Thyroid Cancer (PTC) In a Patient With Germline RET Mutation
por: Vaghasia, Nishit, et al.
Publicado: (2023)

A Case of Medullary Thyroid Carcinoma with de novo V804M RET Germline Mutation
por: Choi, Young Sik, et al.
Publicado: (2013)

Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study
por: Mathiesen, Jes Sloth, et al.
Publicado: (2019)

Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative
por: Kumarasamy, Vishnu Muthuraj, et al.
Publicado: (2017)

Late-Onset Medullary Thyroid Cancer in a Patient with a Germline RET Codon C634R Mutation
por: Walczyk, Agnieszka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3a5frgdkfertt79q1je3tc3be4